Page 66 - Fertility in Women with Rheumatoid Arthritis Vruchtbaarheid van vrouwen met reumatoïde artritis

Chapter 4
Table 1 - Baseline characteristics of the study patients (n = 162)
Variable
Age, mean ± SD years
Never been pregnant, no. (%) Previous miscarriages, no. (%)
1 2 3
Smoking, no. (%)†
Duration of RA, median (IQR) years RF positive, no. (%)
ACPA positive, no. (%)
Erosions, no. (%)‡
DAS28, mean ± SD
Medication use, no. (%)
MTX in past
NSAIDs periconception Sulfasalazine periconception Prednisone periconception Cumulative DMARDs§
None 1
2
3
≥4 Biologic drugs¶ Past
Current
Value
32.3 ± 3.9 80 (49.4)
15 (9.3)
5 (3.1)
2 (1.2)
21 (13.0) 4.9 (2.6 - 10.6) 114 (70.4) 103 (63.6)
86 (53.1) 3.65 ± 1.14
114 (70.4) 47 (29.0) 54 (33.3) 60 (37.0)
17 (10.5) 42 (25.9) 54 (33.3) 34 (21.0) 15 (9.3)
23 (14.2) 7 (4.3)
Patients with missing variables, no. (%)
1 (0.6) -
-
-
-
2 (1.2) 2 (1.2) 1 (0.6) 1 (0.6) 29 (17.9) 1 (0.6)
- - - -
- - - - -
- -
* RA = rheumatoid arthritis; IQR = interquartile range; RF = rheumatoid factor; ACPA = anti-citrullinated protein antibody; DAS28 = Disease Activity Score in 28 joints; NSAIDs = nonsteroidal antiinflammatory drugs. † Smoking status (yes/no) during the preconception period, as reported by the patient.
‡ Presence of erosions, as reported by the patient.
§ Cumulative number of different disease-modifying antirheumatic drugs (DMARDs) taken prior to the preconception visit, including both conventional DMARDs (methotrexate (MTX), sulfasalazine, hydroxycholorquine, gold, prednisone, azathioprine, and leflunomide) and biologic agents.
¶ Use of biologic drugs (etanercept, adalimumab, anakinra, and infliximab) in the past, or current use of biologic drugs (etanercept, adalimumab, and anakinra) during the preconception period.
Univariate analysis
Univariate analyses with the 9 variables of interest showed that women who miscarried were signi cantly older (mean ± SD age 33.9 ± 3.9 years) than women with an ongoing pregnancy (age 32.0 ± 3.8 years; P = 0.022) (Table 2). A larger proportion of women who miscarried were ACPA positive compared to those who had not miscarried (82% versus 60%), although the difference was not signi cant (P = 0.058).
64